Statin use and incident cardiovascular events in renal transplant recipients.

ABSTRACT:

Background

Statins achieve potent LDL lowering in the general population leading to a significant cardiovascular (CV) risk reduction. In renal transplant recipients (RTR) statins are included in treatment guidelines, however, conclusive evidence of improved cardiovascular outcomes has not been uniformly provided and concerns have been raised about simultaneous use of statins and the immunosuppressant cyclosporine. This study aimed to elucidate the effect of statins on a compound CV endpoint, comprised of ischaemic CV events and CV mortality in RTR, with subgroup analysis focussing on cyclosporine users.

Method

622 included RTR (follow-up 5.4 years) were matched based on propensity scores and dichotomized by statin use. Survival analysis was conducted.

Results

Cox regr

SUBMITTER: Anderson JLC 

PROVIDER: S-EPMC8596424 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature